Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Bar-Or

Showing results (21-30 of 409) with videos related to

Pageof 41
Sort By:
Clinical Immunology (Orlando, Fla.)|April 1, 2011
Laquinimod in multiple sclerosisPaul S Giacomini, Amit Bar-Or
The New England Journal of Medicine|July 11, 2003
Do myelin-directed antibodies predict multiple sclerosis?Jack P Antel, Amit Bar-Or
Neurology|August 6, 2013
Premature immune senescence in children with MS: Too young to go steadyAmit Bar-Or, Paolo A Muraro
The Lancet. Neurology|July 31, 2023
NfL is ready for translation into paediatricsSimon Thebault, Amit Bar-Or, Brenda Banwell
Neurology|May 25, 2021
Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE StudyAmit Bar-Or, Ann Herman, Daniela Stokmaier
Scientific Reports|September 10, 2020
Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow)Ayman Rezk, Rui Li, Amit Bar-Or
Arquivos De Neuro-Psiquiatria|April 9, 2008
Beta interferons in clinically isolated syndromes: a meta-analysisAilton Melo, Bernardo Rodrigues, Amit Bar-Or
Expert Review of Clinical Immunology|May 19, 2010
B-cell subsets: cellular interactions and relevance in multiple sclerosisClaudia J Calder, Martin Duddy, Amit Bar-Or
Journal of Neurology|November 19, 2004
What do we know about the mechanism of action of disease-modifying treatments in MS?Hans-Peter Hartung, Amit Bar-Or, Yannis Zoukos
Neurology(R) Neuroimmunology & Neuroinflammation|May 17, 2020
COVID-19 and MS disease-modifying therapiesJoseph R Berger, Rachel Brandstadter, Amit Bar-Or
Pageof 41

Showing results (21-30 of 409) with videos related to

Sort By:
Pageof 41
Clinical Immunology (Orlando, Fla.)|April 1, 2011
Laquinimod in multiple sclerosisPaul S Giacomini, Amit Bar-Or
The New England Journal of Medicine|July 11, 2003
Do myelin-directed antibodies predict multiple sclerosis?Jack P Antel, Amit Bar-Or
Neurology|August 6, 2013
Premature immune senescence in children with MS: Too young to go steadyAmit Bar-Or, Paolo A Muraro
The Lancet. Neurology|July 31, 2023
NfL is ready for translation into paediatricsSimon Thebault, Amit Bar-Or, Brenda Banwell
Neurology|May 25, 2021
Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE StudyAmit Bar-Or, Ann Herman, Daniela Stokmaier
Scientific Reports|September 10, 2020
Multiplexed detection and isolation of viable low-frequency cytokine-secreting human B cells using cytokine secretion assay and flow cytometry (CSA-Flow)Ayman Rezk, Rui Li, Amit Bar-Or
Arquivos De Neuro-Psiquiatria|April 9, 2008
Beta interferons in clinically isolated syndromes: a meta-analysisAilton Melo, Bernardo Rodrigues, Amit Bar-Or
Expert Review of Clinical Immunology|May 19, 2010
B-cell subsets: cellular interactions and relevance in multiple sclerosisClaudia J Calder, Martin Duddy, Amit Bar-Or
Journal of Neurology|November 19, 2004
What do we know about the mechanism of action of disease-modifying treatments in MS?Hans-Peter Hartung, Amit Bar-Or, Yannis Zoukos
Neurology(R) Neuroimmunology & Neuroinflammation|May 17, 2020
COVID-19 and MS disease-modifying therapiesJoseph R Berger, Rachel Brandstadter, Amit Bar-Or
Pageof 41